Literature DB >> 1255784

Pathogenesis of ascites in mice with peritoneal carcinomatosis.

J Fastaia, A E Dumont.   

Abstract

For clarification of the mechanisms underlying formation of malignant ascites, alterations in lymphatic transport from the peritoneal cavity and in peritoneal capillary permeability to protein were studied sequentially in mice inoculated ip with Ehrlich-Lettre ascites tumor cells. All animals developed detectable ascites within 5-7 days of the injection. Diaphragmatic and retrosternal lymph vessels became radiopaque within 30 hours of the ip injection of radiopaque contrast material in control animals without ascites and in 12 experimental mice receiving contrast material 1-3 days after injection of tumor cells. No lymph vessels were opacified in 3 of 4 animals when contrast material was injected on day 5 or in any animal receiving contrast material on or after day 7 following the tumor cell injection. We determined alterations in peritoneal capillary permeability in the second group by measuring the concentration of iv injected Evans blue dye in eluates of sections of peritoneum and contiguous underlying tissue removed 3 hours after injection of dye. Permeability averaged 1.5 times normal (P = 0.02) by day 3 after tumor cell injection, 2 times normal by day 5, and 3 times normal by day 7; it remained at the final level. Although lymph drainage became impaired within 24 hours of the detection of ascites, a progressive increase in capillary permeability began 2 days earlier and was probably the predominant alteration in pathogenesis of the effusion.

Entities:  

Mesh:

Year:  1976        PMID: 1255784     DOI: 10.1093/jnci/56.3.547

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models.

Authors:  Shan Liao; Jieqiong Liu; Peichun Lin; Tony Shi; Rakesh K Jain; Lei Xu
Journal:  Clin Cancer Res       Date:  2011-01-28       Impact factor: 12.531

2.  A permeability-enhancing factor produced by tumor. The genesis of malignant effusions.

Authors:  R Stein-Werblowsky
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

Review 3.  Some aspects of the metastatic process.

Authors:  R L Carter
Journal:  J Clin Pathol       Date:  1982-10       Impact factor: 3.411

4.  A survey of treatment approaches of malignant ascites in Germany and Austria.

Authors:  C F Jehn; S Küpferling; G Oskay-Özcelik; D Lüftner
Journal:  Support Care Cancer       Date:  2014-12-21       Impact factor: 3.603

5.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Authors:  Peter Jantscheff; Vittorio Ziroli; Norbert Esser; Ralph Graeser; Jessica Kluth; Alena Sukolinskaya; Lenka A Taylor; Clemens Unger; Ulrich Massing
Journal:  Clin Exp Metastasis       Date:  2009-09-26       Impact factor: 5.150

6.  Protean manifestations of pylethrombosis. A review of thirty-four patients.

Authors:  C L Witte; M L Brewer; M H Witte; G B Pond
Journal:  Ann Surg       Date:  1985-08       Impact factor: 12.969

7.  Malignant ascites. Clinical and experimental observations.

Authors:  R N Garrison; L D Kaelin; R H Galloway; L S Heuser
Journal:  Ann Surg       Date:  1986-06       Impact factor: 12.969

8.  Trichosanthes dioica root extract induces tumor proliferation and attenuation of antioxidant system in albino mice bearing Ehrlich ascites carcinoma.

Authors:  Sanjib Bhattacharya; Pallab Kanti Haldar
Journal:  Interdiscip Toxicol       Date:  2011-12

9.  The Ehrlich tumor induces pain-like behavior in mice: a novel model of cancer pain for pathophysiological studies and pharmacological screening.

Authors:  Cassia Calixto-Campos; Ana C Zarpelon; Mab Corrêa; Renato D R Cardoso; Felipe A Pinho-Ribeiro; Rubens Cecchini; Estefania G Moreira; Jefferson Crespigio; Catia C F Bernardy; Rubia Casagrande; Waldiceu A Verri
Journal:  Biomed Res Int       Date:  2013-08-29       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.